Get the latest news, insights, and market updates on SENS (Senseonics Holdings, Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Senseonics Holdings, Inc. Schedules Third Quarter 2025 Earnings Release and Conference Call for November 5, 2025 at 4:30 P.M. Eastern Time
GERMANTOWN, Md., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its third quarter 2025 financial results after market close on Wednesday, November 5, 2025. Management will hold a conference call to review the Company’s third quarter 2025 performance sta Oct 22, 2025 - $SENS
How Recent Developments Are Shaping the Senseonics Investment Story
Senseonics Holdings stock has seen a dramatic shift in analyst sentiment. The consensus price target has surged from $1.43 to $28.60, reflecting growing optimism surrounding the company’s growth trajectory and the potential impact of its Eversense 365 system in the diabetes care landscape. Stay tuned to learn how you can keep abreast of these evolving perspectives and what they could mean for the company’s future. What Wall Street Has Been Saying Analyst commentary on Senseonics Holdings has... Oct 21, 2025 - $SENS
Record Revenue Surge and In-House Distribution Shift Might Change The Case For Investing In Senseonics (SENS)
Senseonics Holdings announced preliminary unaudited revenue of approximately US$8.1 million for the third quarter of 2025, marking a 91% year-over-year increase fueled by record new patient growth in the U.S. and greater investment in direct-to-consumer marketing. The company also confirmed a 1-for-20 reverse stock split and will bring commercialization and distribution of its Eversense 365 CGM system fully in-house, aiming to enhance operational efficiency and patient engagement. We’ll... Oct 10, 2025 - $SENS
A Look at Senseonics (SENS) Valuation Following Revenue Surge and Reverse Stock Split
Senseonics Holdings (SENS) caught market attention after announcing preliminary third-quarter revenue of $8.1 million, up 91% from last year. This growth was propelled by 160% new patient growth in the U.S. and expanded marketing efforts. See our latest analysis for Senseonics Holdings. Senseonics’ robust revenue growth and the move to a 1-for-20 reverse stock split sparked renewed interest among investors, but the share price has swung sharply lately. While the 1-year total shareholder... Oct 8, 2025 - $SENS
Senseonics Announces Preliminary Unaudited Revenue for Third Quarter 2025 and Provides Business Update
Preliminary unaudited revenue of $8.1 million for Q3 2025 Generated record quarterly new patient starts in Q3 2025 Established reverse stock split ratio of 1:20, anticipated to be effective October 17, 2025 GERMANTOWN, Md., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced prelimin Oct 6, 2025 - $SENS
Ascensia Diabetes Care Signs MOU to Transfer Eversense® CGM Distribution to Strategic Partner Senseonics
TOKYO, September 03, 2025--PHC Holdings Corporation (President, Representative Director and CEO: Kyoko Deguchi, TSE: 6523) and its subsidiary Ascensia Diabetes Care, a global diabetes care company, today announced that Ascensia has signed a memorandum of understanding to transfer the commercial operations for Eversense® Continuous Glucose Monitoring (CGM) systems to Eversense maker Senseonics Holdings, Inc. (NYSE American: SENS). The companies are targeting to unite Eversense R&D, manufacturing, Sep 3, 2025 - $SENS
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" lets us enhance your experience and provide personalized content and ads.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple